Home＞ACADEMIA
DPP-4 Inhibitor Prevents Deterioration in Cardiac Diastolic Function in Diabetes Patients: Research Sub-Analysis(May.26.2017)
The dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin significantly inhibited deterioration in cardiac diastolic function in diabetes patients, according to results of a clinical research sub-analysis announced by Saga University on May 24 ...
(LOG IN FOR FULL STORY)
-
- Japanese Society of Hypertension to Verify Results of SPRINT Study Jun.14
- AbbVie’s Novel Hep C Treatment Achieves 100% SVR in Genotype 1 Hepatitis C Patients with Compensated Cirrhosis Jun.13
- Will Formularies Spread in Japan? Some Don’t Think So, but MOF Push Might Give Impetus May.23
-
“Authorized Biosimilars” Could Be Priced at 50% of Originators: Prof.
May.23
- JDS, JGS Publish 1st Guideline for Treatment of Diabetes in the Elderly May.22
- AbbVie Japan Set to Build Up Organization to Gear Up for Oncology Drug Launches: President(Jun.28)
- Japan Sales of Global Pharmas Dipped in 2016? Price Cuts, Sluggish LLPs Weighs: Jiho Tally(Jun.28)
- Drug Makers Moving to Outsource “Pharmaceutical Scouting” to Seek Efficiency: Ex-Sanofi Exec(Jun.28)
- PMDA’s Review-Related Ordinary Loss Nearly Doubled in FY2016(Jun.28)
- Stivarga OK’ed for 2nd-Line HCC, Oldamin for Gastric Varices, Actemra for Shorter Dose Interval(Jun.27)
